Progression-Free Survival (PFS) is often employed as a surrogate endpoint for Overall Survival (OS) in oncology trials to expedite evaluation processes. However, its statistical validity as a surrogat
BackgroundHigh-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent